Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy

• Status: Not yet recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

• Reduce the trauma and the time taken for patient rehabilitation.

• The prevailing trend is to perform a mitomycin- C (MMC)-augmented trabeculectomy and trabeculectomy with ologen implants in a trial to decrease bleb failure as a common post- trabeculectomy complication.

• Is to develop a measurement protocol by OCT-A imaging and characterization of the bleb vascularity changes in glaucoma patients before and after surgery.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Asmaa Ahmed Ali Youssif
• Treatments: Mitomycin; Mitomycins

Criteria

Inclusion Criteria:

• patients older than 18 years of age with primary or secondary open-angle glaucoma.

• Primary OAG (POAG) diagnosed on the basis of IOP measurements more than 21 mmHg, open angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle width), glaucomatous visual field defects consistent with glaucomatous optic disc changes.

• PNAG was diagnosed by the presence of narrow or occludable angle on gonioscopy (Grade 2, or 1 on Schaffer grading system for angle width in at least 180° of the total circumference of the angle in primary position without indentation), glaucomatous optic disc changes, visual field defects and IOP more than 21 mmHg

Exclusion Criteria:

• pregnant or lactating female.

• previous intraocular surgery

• one-eyed patients.

• previous ocular trauma.

• uveitis-induced glaucoma, neovascular glaucoma, aphakic/pseudophakic glaucoma

• systemic connective tissue disease and missing more than 3 follow-up visits.

• Trabeculectomy augmented by either MMC or Ologen implant was indicated to study subjects if they had uncontrolled IOP under maximum antiglaucoma medications (3 antiglaucoma drugs) or due to poor socioeconomic status.